Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 22, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 22, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/22/17 - AbbVie reports 99% cure rate for pan-genotypic Hep C therapy [Sport360]
G/P is a once-daily regimen that combines two distinct antiviral agents- the NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir- dosed once-daily as three oral tablets. However, treatment challenges remain related to the use of ribavirin, "commented Xavier Forns, head of hepatitis unit, Hospital Clinic de Barcelona, Spain.
4/22/17 - Acceleron Pharma, Cambridge, Mass., Dyax, Burlington, Mass., Assigned Patent for Polynucleotides Encoding Actriib Antibody
Acceleron Pharma, Cambridge, Massachusetts, and Dyax, Burlington, Massachusetts, have been assigned a patent developed by seven co-inventors for "polynucleotides encoding an actriib antibody." The co-inventors are Ravindra Kumar, Acton, Massachusetts, Asya Grinberg, Lexington, Massachusetts, Monique Davies, Harpswell, Maine, Diana Martik, Cambridge
4/22/17 - Analyst Activity BTIG Research Initiates Coverage On Cascadian Therapeutics (NASDAQ:CASC) With a Buy
Analyst Ratings For Cascadian Therapeutics (NASDAQ:CASC) Today, BTIG Research initiated coverage on Cascadian Therapeutics (NASDAQ:CASC) with a Buy. There are 1 hold rating, 3 buy ratings on the stock. The current consensus rating on Cascadian Therapeutics (NASDAQ:CASC) is Buy (Score: 2.75) with a consensus target price of $6.00 per share, a potent
4/22/17 - Analyst Activity Cantor Fitzgerald Reiterates Buy on Aurinia Pharmaceuticals (NASDAQ:AUPH)
Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH) Today, Cantor Fitzgerald reiterated its Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a price target of $14.00. There are 7 buy ratings on the stock. The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $11.00
4/22/17 - AP Top Health News at 2:46 a.m. EDT
Future of revamped health care bill remains dubious in House FDA approves 2nd near-copy of Remicade for immune disorders Indian public health group loses permit for foreign funds Lawmakers revisiting requiring those on Medicaid to work FDA further restricts pain medication use in kids Italy upholds vaccine requirements for preschoolers Germ in raw.
4/22/17 - Arbutus Announces ARB-1467 Data Presentation at EASL
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, presented results of the first three cohorts of a Phase II study of its RNAi agent, ARB-1467, at the European Association for the Study of the Liver in Amsterdam, The Netherlands.. We are very pleased to present updated Phase II results for ARB-
4/22/17 - Astellas to Acquire Ogeda SA
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week- Astellas Pharma Inc. and Ogeda SA announced that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire Ogeda a privately owned drug discovery company. Under the agreement, Astellas has agreed to pay up to a total
4/22/17 - Bicycle Therapeutics Announces A Candidate Preclinical Milestone In Its Ophthalmology Alliance With ThromboGenics [Syrian Arab News Agency]
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology...
4/22/17 - Biofarma to invest $5 mln in development of new drugs over five years [Tehran Times (Iran)]
Biofarma LLC manufacturer of blood products intends to invest $5 million in the development of new medicines within five years, company president Kostiantyn Yefymenko has said at a press conference at the enterprise in Bila Tserkva. "In the next five years we will spend $5 million on the development of new drugs and conducting preclinical trials,"
4/22/17 - Drug companies lied about dangers of opioids, St. Clair County prosecutor claims in lawsuit [St. Louis Post-Dispatch]
St. Clair County State's Attorney Brendan Kelly filed the 159- page suit Thursday against Purdue Pharma and Abbott Laboratories, accusing them of deceptive advertising and consumer fraud that contributed to opioid and heroin overdoses while maximizing their profit. Similar lawsuits against Purdue and other pharmaceutical companies have been filed b
4/22/17 - Events
A Free Shred Day hosted by Fibre Federal Credit Union takes place from 10 a.m. to 2 p.m. Saturday, April 22, at 812 12th Ave., behind the main branch of Fibre Federal Credit Union. A fundraiser to benefit the Rainier Junior/Senior High School History Club takes place from 8 a.m. to 4 p.m. Saturday, April 22, in the J&R Sales Parking Lot, 215 W B St
4/22/17 - ICYMI: Sen. Brown 'Leading Charge' to Bring Down Drug Prices
In case you missed it, the Huffington Post today released a story highlighting U.S. Sen. In March, Brown introduced sweeping prescription drug legislation the Huffington Post notes, "combines every policy idea drug lobbyists hate." The legislation follows specific steps Brown outlined to Trump in a December 2016 letter outlining specific steps his.
The Ministry of Finance, Government of India, has exempted customs duty for 27 medicines that are supplied free of cost by pharmaceutical companies under their patient assistance programmes. Of these medicines, 17 are used in treatment of various kinds of cancers, like blood, prostrate and ovarian. This notification is applicable only to medicines
4/22/17 - IPA urges health ministry to enforce barcode on drug packs before regulating sale of drugs through e-portal [Sport360]
The Indian Pharmaceutical Association has urged the Union health ministry to make it compulsory for pharmaceutical industry to implement barcoding on medicine packs to ensure tracking and tracing of the products before framing a regulation to facilitate uploading sale data on the e-platform. At this moment it would not be practical to implement it
4/22/17 - Marathon exits powerful lobbying group after $89,000 drug-pricing controversy [Chicago Tribune]
April 22 Northbrook- based Marathon Pharmaceuticals has dropped out of the pharmaceutical industry's main lobbying group following controversy over the company's recent attempt to price a muscular dystrophy drug at $89,000 a year. Holly Campbell, a spokeswoman for the Pharmaceutical Research and Manufacturers of America, confirmed Friday that...
4/22/17 - Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors [T-break Tech (Middle East)]
Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of Kentucky has enrolled the first patient into a new phase 1 study of CA4P in combination with everolimus for the treatment of neuroendocrine.
4/22/17 - Mindset change may be needed to slow craving Change in mindset might be needed to prevent addiction
Much has been made about opioid addition and there is no shortage of finger pointing about the causes. Some are blaming patients, as though the addicted person is to blame for craving the medication he or she was initially prescribed. Others blame the doctors or pharmaceutical companies as if the patient didn t have a mind of his or her own.
4/22/17 - Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress? 2017
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that the embargo on its late-breaker abstract discussing preliminary data from a Phase 2 clinical trial of its lead product candidate A4250 in children with cholestatic liver disease has been lifted and the data will be..
4/22/17 - Rep. Stivers Introduces Speeding Access to Already Approved Pharmaceuticals Act
Steve Stivers, R- Ohio, has introduced the Speeding Access to Already Approved Pharmaceuticals Act to "require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union." Steve Stivers in Washington at 1022 Longworth House Office Building, Washington, DC 20515; 202/ 225-2015; or in
4/22/17 - Reports Summarize Subarachnoid Hemorrhage Study Results from Beth Israel Deaconess Medical Center (Predictors of Shunt Insertion in Aneurysmal...
Reports Summarize Subarachnoid Hemorrhage Study Results from Beth Israel Deaconess Medical Center. Our news journalists obtained a quote from the research from Beth Israel Deaconess Medical Center, "An exploratory analysis of 149 patients enrolled in the CARAS study was performed in an effort to identify factors predictive of permanent CSF diversio
4/21/17 - $3 million awarded to widow who sued pharmaceutical firm over husband's suicide [Chicago Tribune]
April 21 A Glencoe woman hugged her attorneys after a jury in Chicago awarded her $3 million Thursday in a lawsuit against a pharmaceutical company that she blamed for her husband's suicide. Wendy Dolin's husband, Stewart, stepped in front of a CTA Blue Line train in the Loop on July 15, 2010. Stewart Dolin was a corporate attorney and a partner
4/21/17 - $3M award in suit against drug company over man's suicide
CHICAGO A suburban Chicago woman has been awarded $3 million in a lawsuit against a pharmaceutical company she blamed for her husband's suicide.
4/21/17 - 3D Swing Mixers Manufacturer for Combining Pharmaceutical Powders in Drug Development and Manufacturing [Sudan Tribune]
Promector is an equipment manufacturer delivering numerous pharmaceutical and diagnostics instruments, including 3 D swing powder mixers. The Promix uniquely mixes powders based on a continuous circulation in the mixing tank without the need for paddles or stirrers. Mixers are suitable for dry, powdery materials such as those used in the pharmaceut
4/21/17 - ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures
By a News Reporter-Staff News Editor at Drug Week ABL, Inc., a global contract research and manufacturing service provider to the U.S. Government and biopharmaceutical industry, announced it has been awarded a five-year, indefinite delivery/indefinite quantity contract# HHSO100201600019I entitled "Respiratory Illness Live Virus Fill/Finish Servic
4/21/17 - Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the pricing of its previously announced underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $3.50..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement